Rochester MN 胰腺癌临床试验
22项针对 胰腺癌的研究正在 Rochester及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
招募中2 期
- Mayo Clinic in Rochester, Rochester
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
招募中1 期
- Mayo Clinic Rochester, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
招募中观察性研究
- Mayo Clinic Rochester, Rochester
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
招募中2/3 期
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
- Mayo Clinic, Rochester
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
招募中3 期
- Mayo Clinic Cancer Center, Rochester
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
招募中1/2 期
- Mayo Clinic, Rochester
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
招募中观察性研究
- Mayo Clinic in Rochester, Rochester
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
招募中2 期
- Mayo Clinic Rochester, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
招募中2 期
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
招募中2 期
- Mayo Clinic in Rochester, Rochester
CREO - Microwave Ablation Feasibility Study
招募中
- Mayo Clinic Rochester, Rochester
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
招募中观察性研究
- Mayo Clinic in Rochester, Rochester
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
招募中2 期
- Mayo Clinical Rochester, Rochester
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
招募中1 期
- Mayo Clinic, Rochester
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
招募中2 期
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
招募中1/2 期
- Mayo Clinic Rochester, Rochester
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
招募中观察性研究欢迎健康志愿者
- Mayo Clinic in Rochester, Rochester
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
招募中观察性研究
- Mayo Clinic in Rochester, Rochester
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
招募中2 期
- Ohio State University Telemedicine, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
招募中观察性研究欢迎健康志愿者
- Mayo Clinic, Rochester
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
招募中1/2 期
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
招募中1 期
- Exelixis Clinical Site #14, Rochester
其他城市的 胰腺癌试验
- Houston, TX61 项研究
- New York City, NY60 项研究
- Boston, MA43 项研究
- Nashville, TN39 项研究
- Los Angeles, CA35 项研究
- St. Louis, MO33 项研究
- Arlington, VA33 项研究
- Baltimore, MD31 项研究
- San Antonio, TX31 项研究
- Philadelphia, PA26 项研究
- Tampa, FL26 项研究
- Durham, NC24 项研究
Rochester的其他研究
- 乳腺癌42 项研究
- 非小细胞肺癌37 项研究
- 转移性癌症31 项研究
- 癌症（所有类型）30 项研究
- 卵巢癌29 项研究
- 结直肠癌29 项研究
- 多发性骨髓瘤24 项研究
- 心力衰竭22 项研究
- 前列腺癌22 项研究
- 子宫内膜癌20 项研究
- 肺癌20 项研究
- 慢性淋巴细胞白血病18 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。